Anticoagulant antidotes near to release

Medications to reverse the effects of the novel anticoagulants are closer to commercial availability, with announcements that phase III trials on the antidotes have started.

    No specific antidotes are available for any of the novel oral anticoagulants if major bleeding occurs or emergency surgery is required for patients on the medication.

    Now, however, the manufacturers of dabigatran (Pradaxa), apixaban (Eliquis) and rivaroxaban (Xarelto) — which are PBS listed for the prevention of atrial fibrillation-related stroke